Journal
JAPANESE JOURNAL OF OPHTHALMOLOGY
Volume 62, Issue 5, Pages 584-591Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s10384-018-0605-6
Keywords
Aflibercept; Age-related macular degeneration; Choroidal vascular hyperpermeability; Polypoidal choroidal vasculopathy
Categories
Funding
- Novartis Pharma
- Alcon
- Bausch Lomb
- Bayer
- Canon
- HOYA
- Kowa
- NIDEK
- Santen Pharmaceutical
- Senju Pharmaceutical
- Topcon
- Wakamoto Pharmaceutical
- Pfizer
- AMO
- Mitsubishi Tanabe Pharma
- XOMA
Ask authors/readers for more resources
Purpose To determine factors predictive of visual outcomes in eyes treated with intravitreal aflibercept injections (IAIs) for typical neovascular age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV). Study design Retrospective, multicenter, institutional, consecutive, interventional case series. Methods One hundred nine eyes (107 patients) with treatment-naive neovascular AMD at 3 university hospitals were studied. After a loading phase of 3 monthly 2.0-mg IAIs, injections were administered every 2 months. The baseline clinical characteristics were investigated in relation to the 12-month visual outcomes. Changes in the mean best-corrected visual acuity (BCVA) were measured at 12 months after initiation of aflibercept therapy. Results Forty-five eyes (41.3%) had typical neovascular AMD, and 64 eyes (58.7%) had PCV. The changes in the mean BCVA at 12 months compared with baseline did not differ significantly (P = .737) between the 2 groups. Stepwise analysis showed that larger gains in the BCVA at 12 months were associated with poor BCVA (P < .001), no pigment epithelial detachment (P = .004), and subretinal fluid (P = .039) at baseline in eyes with typical neovascular AMD; larger gains in the BCVA were associated with poorer BCVA (P < .001), presence of choroidal vascular hyperpermeability (CVH) (P = .013), and subretinal fluid (P = .044) at baseline in eyes with PCV. Conclusions Although poorer BCVA and the presence of subretinal fluid predicted larger gains in BCVA in both subtypes treated with aflibercept, eyes with typical neovascular AMD had greater improvement if no pigment epithelial detachment was present, while eyes with PCV had greater improvement if CVH was present.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available